Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0278488 (metastatic breast cancer)
 7,812 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p.o. twice a day with hydrocortisone 40 mg p.o./day. All pts were postmenopausal, mean age 63 years, and pretreated with cytostatics and/or hormones. Dominant sites of metastases were: soft tissues 29 pts. bone 12 pts. lungs 6 pts. Objective responses were: 4 (7.4%) CR, 15 (27.8%) PR, 16 (29.6%) NC and 19 (35.2%) PD (UICC criteria). The response (CR + PR) at metastatic sites was: soft tissues 12 (41%), bone 4 (33%). The mean response duration was 15.0 months for CR; 10.2 for PR and 5.5 months for NC. The results of the study confirm that low--dose aminoglutethimide is an effective second-line hormonal treatment of advanced breast cancer.
Ginekol Pol 1994 Sep
PMID:[Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer]. 772 Nov 64

The aim of this study was to assess effects of second-line chemotherapy in metastatic breast cancer via determination of CA 15-3 marker. Analysis included 73 women, in whom distant metastases were diagnosed within 14-72 months (median: 43) after the completion of basic therapy. Average age of patients at primary diagnosis was 50.7 +/- 12.6 years. Dominant sites of metastases were: liver (27 patients) and lungs (24 patients). Serum CA 15-3 was examined immunoenzymatically at diagnosis of distant metastases and then after 2-4 cycles (median 4) of anthracycline-based chemotherapy. Changes of mean CA 15-3 values correlated with the UICC response criteria. There was a significant fall in mean levels of CA 15-3 after treatment in patients with complete (p < 0.004) and partial regression of metastatic lesions (p < 0.03). Stabilization and progression of the disease were associated with raise in CA 15-3 mean values, but the difference was significant only in the latter group (p < 0.02). In 31 out of 39 patients (79.5%) with regressive disease (complete and partial response) CA 15-3 levels decreased by at least 25% after treatment. Nine of 11 (81.8%) patients with stable disease had the antigen concentrations that did not vary by more than +/- 25% of the initial CA 15-3 value. CA 15-3 levels raised by at least 25% in 22 out of 23 (95.7%) cases with progressive breast cancer. Overall, CA 15-3 variations correlated with the disease status in 62 (84.9%) patients. These findings confirmed the usefulness of CA 15-3 determinations in evaluating the efficacy of second-line chemotherapy in patients with advanced breast cancer.
Pol Arch Med Wewn 1997 Apr
PMID:[Usefulness of CA 15-3 antigen determination for evaluation of response to second-line chemotherapy in patients with breast cancer: preliminary study]. 941 11

The presented case is breast cancer metastatic into the paranasal sinuses. Accompanied symptoms suggested thrombosis of cavernosus sinus with very fast growing eye and neurological symptoms caused by metastases to brain tissue. Breast cancer metastatic into the paranasal sinuses is extremely rare and usually ends with death, as it is a result of neoplastic dissemination and does not react to systemic treatment. This type of neoplasm was for the first time presented in literature by Robin in 1938. Until 1994 nine cases of patients suffering from this type of neoplasm have been described. All of them died.
Otolaryngol Pol 1998
PMID:[Breast carcinoma metastasis to paranasal sinuses]. 981 34

The study was performed for answering the question whether metastatic breast cancer has the same overexpression of HER2/neu as primary breast tumor. We assumed that study on this subject could give a valuable information for proper interpretation of HER2/neu overexpression in breast cancer patients designated for therapy with Herceptin. Our study was performed on 71 breast cancer patients qualified for clinical trial with Herceptin therapy. All patients selected for this trial have had surgery and two episodes of unsuccessful adjuvant therapy. Tissue samples were routinely fixed in 4% formalin and embedded in paraffin. Immunohistochemical assays were performed on 5 microns slides using DAKO HercepTest and semi-quantitative methods to determine HER2 protein overexpression were used. All study cases were subdivided into two groups. First group--49 cases in which expression of HER2 was examined in tissue from primary breast tumors, and second group--22 cases in which expression of HER2 was examined in tissue from metastatic lesions. In the whole study group (71 cases) overexpression was confirmed in 29 (40.8%) cases. In the group of primary breast tumors overexpression of HER2 was present in 20 (40.8%) of cases. In the group of metastatic breast tumors overexpression of HER2 was present in 9 (40.9%) of cases. The result suggests that overexpression which appears in primary breast carcinoma is also preserved in metastases. Direct prove of such a conclusion, would be a study on HER2/neu expression estimated in primary and metastases in the same patients. It requires a proper quantity and quality of material. Our results indicate that there is no difference between the estimation of HER2/neu overexpression in primary and metastatic breast cancer in patients with disseminated disease after double failure of chemotherapy. Evaluation of overexpression of HER2/neu in cases of planned Herceptin therapy can be done both in material from primary and from metastatic tumor.
Pol J Pathol 2001
PMID:Expression of HER2/neu in primary and metastatic breast cancer. 1150 77

Overexpression of the Erb B-2 receptor plays an important role in the pathogenesis of breast cancer. It results in the formation of heterodimers consisting of Erb-B2/Erb B-3 receptors which have an ability to produce stable and external factors independent mitotic stimuli. Together with an autocrine stimulation of neoplastic cell proliferation by heregulin and cyclooxygenase 2 activation it is a significant factor in carcinogenesis. Overexpression of Erb B-2 seems to be an independent negative prognostic factor in breast cancer. Its predictive value is not clear-cut. It is suggested that breast cancer showing Erb B-2 overexpression is more sensitive to treatment with anthracyclines and less to CMF. The anti-Erb B-2 monoclonal antibody (trastuzumab) is used in treatment of metastatic breast cancer both as a single drug and in combination with chemotherapy.
Ginekol Pol 2003 Apr
PMID:[Erb-2 overexpression in breast cancer]. 1291 78

Amyloidosis is a generic term for a heterogeneous group of disorders associated with deposition of protein in an abnormal fibrillar form. We report a case of kappa L-chain primary lung amyloidosis. A 44-year-old woman without symptoms. Roentgenogram and computed tomography of the chest showed several small nodular shadows. The mammography revealed tumor of the breast and the metastatic breast cancer have been suspected. After the quadrantectomy the breast tumor has been diagnosed as adenoma. The diagnosis of pulmonary amyloidosis was established by an open lung biopsy. Immunohistochemistry revealed amyloid light (AL) of kappa-light chain origin. Serum protein electrophoresis was negative for monoclonal gammapathy. Over the next 6 years, the patient remained relatively asymptomatic. The case illustrates the problems with diagnosis of multiple solitary nodules and the long and relatively benign course of primary pulmonary amyloidosis.
Pol Merkur Lekarski 2008 Dec
PMID:[A case of kappa L-chain primary nodular lung amyloidosis]. 1920 85

S100A4 is a member of the S100 family of calcium-binding proteins that is directly involved in tumor metastasis. In the present study, we examined the potential role of S100A4 in metastasis in breast cancer and its relation with matrix metalloproteinase-13 (MMP-13). Analysis of 100 breast cancer specimens including 50 with and 50 without lymph node metastasis showed a significant upregulation of S100A4 and MMP-13 expression in metastatic breast cancer tissues. Positive immunoreactivity for S100A4 was associated with MMP-13 expression. Overexpression of S100A4 in the MDA-MB-231 breast cancer cell line upregulated MMP13 expression leading to increased cell migration and angiogenesis. SiRNA-mediated silencing of S100A4 downregulated MMP13 expression and suppressed cell migration and angiogenesis. Moreover, neutralization of MMP-13 activity with a specific antibody blocked cell migration and angiogenesis in MDA-MB-231/S100A4 cells. In vivo siRNA silencing of S100A4 significantly inhibited lung metastasis in transgenic mice. The present results suggest that the S100A4 gene may control the invasive potential of human breast cancer cells by modulating MMP-13 levels, thus regulating metastasis and angiogenesis in breast tumors. S100A4 could therefore be of value as a biomarker of breast cancer progression and a novel therapeutic target for human breast cancer treatment.
Acta Biochim Pol 2012
PMID:S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13. 2316 4

Plau codes for the urokinase-type plasminogen activator (uPA), critical in cancer metastasis. While the mechanisms driving its overexpression in tumorigenic processes are unknown, it is regulated by the AP-1 transcriptional complex in diverse situations. The AP-1 component Fra-1 being overexpressed in aggressive breast cancers, we have addressed its role in the overexpression of Plau in the highly metastatic breast cancer model cell line MDA-MB231 using ChIP, pharmacological and RNAi approaches. Plau transcription appears controlled by 2 AP-1 enhancers located -1.9 (ABR-1.9) and -4.1 kb (ABR-4.1) upstream of the transcription start site (TSS) of the uPA-coding mRNA, Plau-001, that bind Fra-1. Surprisingly, RNA Pol II is not recruited only at the Plau-001 TSS but also upstream in the ABR-1.9 and ABR-4.1 region. Most Pol II molecules transcribe short and unstable RNAs while tracking down toward the TSS, where there are converted into Plau-001 mRNA-productive species. Moreover, a minority of Pol II molecules transcribes a low abundance mRNA of unknown function called Plau-004 from the ABR-1.9 domain, whose expression is tempered by Fra-1. Thus, we unveil a heretofore-unsuspected transcriptional complexity at Plau in a reference metastatic breast cancer cell line with pleiotropic effects for Fra-1, providing novel information on AP-1 transcriptional action.
...
PMID:Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer. 2520 76

Breast cancer has high metastatic potential with distant metastases involving mainly lungs, liver and bones. Less frequently it gives distant spread to other organs. Herein we would like to present a very rare case of an acute cholecystitis which turned out to be a metastatic breast cancer in previously healthy woman. A female patient, 64-years old, presented to the emergency department with symptoms of biliary colic and acute abdomen. During the emergency cholecystectomy, we diagnosed the gallbladder empyema with thickened wall. There were also multiple metastatic nodules in the peritoneal cavity and an excessive amount of free fluid. The emergency physicians diagnosing female patient with the acute abdominal symptoms and a breast cancer history might suspect malignant spread into abdominal organs including gallbladder. On the other hand, acute cholecystitis symptoms might be the first symptoms of metastatic process in the gallbladder from the unknown primary source, which may be breast.
Pol Przegl Chir 2017 Aug 31
PMID:Patient with metastatic breast cancer presenting as acute cholecystitis with one-year survival on hormonotherapy. 2890 8

Preoperative systemic therapy including neoadjuvant chemotherapy (NCT) is standard treatment in locally advanced breast cancer (LABC), the aim of which is to enable a radical surgery and to reduce the risk of local and distant recurrence. It has been established that NCT in LABC may effectively induce apoptosis. The study objective was to assess the role of a proapoptotic second mitochondria-derived activator of apoptosis (SMAC) in LABC. The study group comprised 56 patients with advanced non-metastatic breast cancer (stage IIB -node positive and III), who received NCT followed by surgery and adjuvant treatment. Expression of SMAC protein was analysed using the immunohistochemistry technique in core biopsies sampled from the patients' breasts before NCT and in surgical specimens collected after completion of NCT. Expression of SMAC was significantly higher in the breast cancer specimens after NCT (p < 0.01). High expression of SMAC in the core biopsy before NCT correlated with a pathological complete remission (pCR, p < 0.01). The patients with a high expression of SMAC in the surgical specimens after NCT had longer DFS. Our study proves a potential role of SMAC expression in LABC as a novel favourable prognostic factor in LABC for pCR and disease-free survival (DFS).
Pol J Pathol
PMID:SMAC protein expression as a potent favorable prognostic factor in locally advanced breast cancer. 2989 24


1 2 Next >>